July 28, 2026
Antibodies up, trust issues too
New HIV vaccine shows unprecedented success in preclinical study
Big lab win, but the comments are screaming: wake us up when human results land
TLDR: A new HIV vaccine produced unusually strong virus-fighting antibodies in monkeys, and human trials are now underway. Commenters are split between cautious hope and eye-rolling skepticism, with many arguing that better access to existing HIV-prevention medicine matters just as much right now.
Scientists at La Jolla Institute for Immunology and Scripps are celebrating a huge preclinical win: a new HIV vaccine got monkeys to produce an unusually strong batch of antibodies that can fight many versions of the virus. That’s a big deal because HIV is famously slippery, constantly changing and hiding from the immune system. Researchers are calling it a ground-up success story years in the making, and human trials have already begun.
But in the comments? The mood is less champagne, more "we’ve been hurt before". One camp is cautiously hopeful, basically saying, good news, but please don’t make us fall in love with another early-stage HIV vaccine headline. Several readers zeroed in on the fine print: this was in rhesus macaques, and one commenter flatly noted it worked well in 44% of them, which instantly cooled the victory parade. Another summed up the vibe with brutal honesty: Phase I is where most HIV vaccines die.
Then came the real drama: some commenters argued the bigger scandal isn’t the lack of a vaccine at all, but the lack of political will to expand PrEP—medicine people can take to prevent HIV infection. That turned the thread from science celebration into a mini public-health cage match: should we hype the moonshot, or fix access to tools that already work? The result was peak internet energy: hope, skepticism, wonky policy rage, and a lot of people saying, in so many words, call us when there are human data.
Key Points
- •LJI, Scripps Research, and IAVI reported a preclinical HIV vaccine result in non-human primates that generated high numbers of broadly neutralizing antibodies.
- •The article describes this as the first HIV vaccine to produce a high number of broadly neutralizing, virus-fighting antibodies in primates.
- •The study was published in *Nature* and is presented as the result of 14 years of collaboration between LJI and Scripps Research through CHAVD.
- •The vaccine strategy works by guiding B cell maturation so immune cells can better target vulnerable parts of HIV.
- •The article says human trials of the vaccine have already started.